How does RHO6's pe Ratio compare to its peers?

RHO6 is expensive based on its Price-To-Earnings Ratio (28.7x) compared to the peer average (24x).

How does RHO6's pe Ratio compare vs other companies in the European Pharmaceuticals Industry?

RHO6 is expensive based on its Price-To-Earnings Ratio (28.7x) compared to the European Pharmaceuticals industry average (22.7x).

What is RHO6's pe Ratio compared to its Fair pe Ratio? This is the expected pe Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RHO6 is expensive based on its Price-To-Earnings Ratio (28.7x) compared to the estimated Fair Price-To-Earnings Ratio (26.9x).

What is the Fair Price of RHO6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

RHO6 (€39.5) is trading below our estimate of [[fair value]] (€95.84)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Roche Holding (DB:RHO6) - Stock Price, News & Analysis

RHO6 Stock Overview

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. More details

RHO6 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	1/6
Financial Health	4/6
Dividends	4/6

Rewards

Trading at 58.8% below our estimate of its fair value

Earnings are forecast to grow 14.6% per year

Risk Analysis

Has a high level of debt

Dividend of 3.25% is not well covered by earnings

Profit margins (13.3%) are lower than last year (19%)

Large one-off items impacting financial results

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Roche Holding AG Competitors

Merck KGaA

XTRA:MRK

€58.9b

Dermapharm Holding

XTRA:DMP

€2.1b

Novartis

SWX:NOVN

CHF 193.9b

AstraZeneca

LSE:AZN

UK£181.5b

Price History & Performance

Summary of share price highs, lows and changes for Roche Holding
Historical stock prices
Current Share Price	CHF 39.04
52 Week High	CHF 39.40
52 Week Low	CHF 27.10
Beta	0.18
1 Month Change	8.67%
3 Month Change	17.12%
1 Year Change	29.26%
3 Year Change	-5.75%
5 Year Change	8.60%
Change since IPO	275.34%

Recent updates

Shareholder Returns

	RHO6	DE Pharmaceuticals	DE Market
7D	0.5%	0.6%	-0.6%
1Y	29.3%	-16.8%	14.8%

Return vs Industry: RHO6 exceeded the German Pharmaceuticals industry which returned -16.8% over the past year.

Return vs Market: RHO6 exceeded the German Market which returned 14.8% over the past year.

Price Volatility

Is RHO6's price volatile compared to industry and market?
RHO6 volatility
RHO6 Average Weekly Movement	4.1%
Pharmaceuticals Industry Average Movement	4.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.6%

Stable Share Price: RHO6 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: RHO6's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1896	103,249	Thomas Schinecker	www.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions.

Roche Holding AG Fundamentals Summary

How do Roche Holding's earnings and revenue compare to its market cap?
RHO6 fundamental statistics
Market cap	€254.81b
Earnings (TTM)	€8.81b
Revenue (TTM)	€66.41b

28.7x

P/E Ratio

3.8x

P/S Ratio

Is RHO6 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RHO6 income statement (TTM)
Revenue	CHF 62.40b
Cost of Revenue	CHF 15.73b
Gross Profit	CHF 46.66b
Other Expenses	CHF 38.39b
Earnings	CHF 8.28b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Jul 24, 2025

Earnings per share (EPS)	10.41
Gross Margin	74.79%
Net Profit Margin	13.27%
Debt/Equity Ratio	95.9%

How did RHO6 perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

93%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/22 02:23
End of Day Share Price	2025/02/20 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Roche Holding AG is covered by 58 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamla Singh	AlphaValue
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research

RHO6 Stock Overview

Rewards

Risk Analysis

Roche Holding AG Competitors

XTRA:MRK

€58.9b

XTRA:DMP

€2.1b

SWX:NOVN

CHF 193.9b

LSE:AZN

UK£181.5b

Price History & Performance

Recent News & Updates

Roche Unveils New Class of Next-Generation Sequencing with Its Novel Sequencing by Expansion Technology

Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(K) Clearance

Legacy Pharma Inc. SEZC acquired InterMune, Inc. from Roche Holding AG (SWX:ROG).

Roche Announces FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

Roche Receives FDA Approval for the First Companion Diagnostic to Identify Patients with HER2-ultralow Metastatic Breast Cancer Eligible for ENHERTU

Roche Holding AG Reports Earnings Guidance for the Year 2025

Recent updates

Roche Unveils New Class of Next-Generation Sequencing with Its Novel Sequencing by Expansion Technology

Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(K) Clearance

Legacy Pharma Inc. SEZC acquired InterMune, Inc. from Roche Holding AG (SWX:ROG).

Roche Announces FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

Roche Receives FDA Approval for the First Companion Diagnostic to Identify Patients with HER2-ultralow Metastatic Breast Cancer Eligible for ENHERTU

Roche Holding AG Reports Earnings Guidance for the Year 2025

Roche Announces Executive and Committee Changes

Roche's Itovebi Demonstrates Statically Significant and clinically meaningful Overall Survival Benefit in A Certain Type of HR-Positive Advanced Breast Cancer

Roche Receives FDA Clearance with CLIA Waiver for Cobas® liat Molecular Tests to Diagnose Sexually Transmitted Infections At the Point of Care

Roche Receives FDA Clearance For VENTANA DP 600 Slide Scanner In Digital Pathology

Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025

Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions

New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma

Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A